Market Strategy
Articles
News
Daily Comment
Visie Van De Week
Real-time charts
Contact
About us
Links
Market Strategy
Articles
News
Daily Comment
Visie Van De Week
Real-time charts
Contact
About us
Links
Market Strategy
Articles
News
Daily Comment
Visie Van De Week
Real-time charts
Market Strategy
Articles
News
Daily Comment
Visie Van De Week
Real-time charts
About us
Contact
Links
About us
Contact
Links
Accordion Title
Accordion Content
more items +
Ackman’s Pershing Square USA says IPO is still happening, despite NYSE delay notice
S&P 500’s turbulent week ends with stocks rallying after inflation report
Why CrowdStrike is likely shielded from billions in customer losses caused by its outage
Some of the most popular trades of 2024 are coming undone after reaching ‘stupid’ levels
Why Zelle scams concern lawmakers so much — and how they could affect you
Olympians’ families turn to GoFundMe in a race to get to Paris: ‘How would we miss this?’
DexCom’s stock is headed for its worst selloff ever. Not everyone thinks it’s justified.
Beware of bears selling shorts
Why ‘dog days’ of summer can be harsh for these bonds
Don’t know what your Social Security benefits will be? Uh oh.
What to make of this week’s action in the stock market and the ‘Great Rotation’
Commodity markets fear a repeat of China’s 2015 economic slowdown
Ackman’s Pershing Square USA says IPO is still happening, despite NYSE delay notice
S&P 500’s turbulent week ends with stocks rallying after inflation report
Why CrowdStrike is likely shielded from billions in customer losses caused by its outage
Some of the most popular trades of 2024 are coming undone after reaching ‘stupid’ levels
Why Zelle scams concern lawmakers so much — and how they could affect you
Olympians’ families turn to GoFundMe in a race to get to Paris: ‘How would we miss this?’
DexCom’s stock is headed for its worst selloff ever. Not everyone thinks it’s justified.
Beware of bears selling shorts
Why ‘dog days’ of summer can be harsh for these bonds
Don’t know what your Social Security benefits will be? Uh oh.
What to make of this week’s action in the stock market and the ‘Great Rotation’
Commodity markets fear a repeat of China’s 2015 economic slowdown
Dow Jones Newswires: Novartis agrees to buy Chinook Therapeutics for up to $3.5 billion
12-06-23
The deal will hand Novartis exposure to Chinook’s pipeline for kidney disease treatments.
Share this on:
